MetaCap

Guardant Health (GH) vs Oscar Health (OSCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oscar Health (OSCR) has outperformed Guardant Health (GH) over the past year, gaining 83.5% versus a gain of 38.3%. Over five years, OSCR leads with a +151.8% price change compared with +36.4% for GH. Guardant Health is the larger company by market cap ($19.73 billion vs $7.68 billion), about 2.6 times the size.

Oscar Health converts more of its revenue into profit, with a net margin of -3.8% versus -42.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GH+38.33%OSCR+83.46%
+170%+68%-35%
Nov 21, 20251 yearNov 20, 2026
GH+49.45%OSCR+140.10%
+239%+70%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GH versus OSCR key metrics
MetricGHOSCR
Share price$145.83$24.73
Market cap$19.73B$7.68B
1-day change+0.16%-5.50%
YTD return+42.77%+72.09%
1-year return+38.33%+83.46%
5-year return+36.39%+151.83%
P/E ratio (TTM)—10.99
Forward P/E—10.09
EPS (TTM)$-3.68$2.25
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$982.02M$11.70B
Revenue growth (YoY)+32.88%+27.50%
Net income (latest FY)$-416.28M$-443.15M
Gross margin64.46%—
Operating margin-44.53%-3.39%
Net margin-42.39%-3.79%
52-week high$191.05$38.50
52-week low$74.55$10.69
Distance from 52-week high-23.67%-35.77%
Analyst consensusstrong_buyhold
Avg. price target upside+37.67%+49.62%
Average volume1.97M5.30M
Shares outstanding135.29M275.51M
Employees2,4902,305
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Guardant Health is about 2.6 times larger than Oscar Health by market value ($19.73B vs $7.68B).
  • OSCR has outperformed GH by 45.1 percentage points over the past year.
  • Oscar Health is more profitable, keeping -3.8 cents of every revenue dollar as net income versus -42.4 cents for Guardant Health.
  • Guardant Health grew revenue faster in its latest fiscal year (+32.88% vs +27.50%).

About Guardant Health

GH stock →

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.

Health Care · Medical Specialities · 2,490 employees

About Oscar Health

OSCR stock →

Oscar Health, Inc. operates as a healthcare technology company in the United States.

Health Care · Medical Specialities · 2,305 employees

GH vs OSCR FAQ

Which is bigger, Guardant Health or Oscar Health?

Guardant Health (GH) is larger, with a market capitalization of $19.73B compared with $7.68B for Oscar Health (OSCR).

Which stock has performed better over the past year, GH or OSCR?

OSCR returned +83.46% over the past 12 months, compared with +38.33% for GH (price return, excluding dividends). Past performance does not predict future results.

Are Guardant Health and Oscar Health in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons